Literature DB >> 15931298

Failure of ischemic neuroprotection by potentiators of gamma-aminobutyric acid.

Ken Madden1, Wayne Clark, Nicola Lessov.   

Abstract

INTRODUCTION: Potentiators of inhibitory neurotransmission may provide a neuroprotective effect on cerebral tissue exposed to ischemia, without inducing toxic side effects. Topiramate and vigabatrin enhance the action of gamma-aminobutyric acid (GABA), and each has side effect profiles known to be well tolerated through their clinical use as anticonvulsant medications. We assessed the potential benefit through GABA activation by these drugs on infarct size and functional recovery following focal cerebral ischemia in mice.
METHODS: Silicon-coated suture was advanced through the internal carotid artery of 89 halothane-anesthetized mice to temporarily occlude the right middle cerebral artery for either 45 minutes (topiramate), or 120 minutes (vigabatrin). Animals were treated either at the time of reperfusion with topiramate (100 mg/kg, 40 mg/kg, or saline control), or two hours before arterial occlusion with vigabatrin, (1000 mg/kg, 500 mg/kg, or saline control). Neurological outcome was measured 24 hours after ischemia using a 28-point functional examination score. Infarct volume was estimated by summing area maps of stained slices of infarcted hemispheres.
RESULTS: Functional examination scores at 24 hours were similar between the high dose topiramate group, the low dose topiramate group, and the control group. Similarly, no differences were noted between examination scores of high dose vigabatrin, low dose vigabatrin, and control. Consistent sized right hemisphere infarcts were noted within each group on histological examination. Mean infarct volumes did not differ between groups treated with high dose topiramate, low dose topiramate, or control. Infarct volumes of animals treated with saline control were slightly larger than that of high dose vigabatrin and low dose vigabatrin groups, but the difference did not reach significance.
CONCLUSION: Treatment with these two potentiators of GABA did not result in significant differences in outcome following focal cerebral ischemia, by either functional or histological measures. These results do not support a substantial neuroprotective role of GABA following ischemia in this mouse suture model.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 15931298      PMCID: PMC1069034          DOI: 10.3121/cmr.1.2.119

Source DB:  PubMed          Journal:  Clin Med Res        ISSN: 1539-4182


  47 in total

1.  Comparative effect of transient global ischemia on extracellular levels of glutamate, glycine, and gamma-aminobutyric acid in vulnerable and nonvulnerable brain regions in the rat.

Authors:  M Y Globus; R Busto; E Martinez; I Valdés; W D Dietrich; M D Ginsberg
Journal:  J Neurochem       Date:  1991-08       Impact factor: 5.372

2.  Release of inhibitory neurotransmitters in response to anoxia in turtle brain.

Authors:  G E Nilsson; P L Lutz
Journal:  Am J Physiol       Date:  1991-07

3.  Inhibition by topiramate of seizures in spontaneously epileptic rats and DBA/2 mice.

Authors:  J Nakamura; S Tamura; T Kanda; A Ishii; K Ishihara; T Serikawa; J Yamada; M Sasa
Journal:  Eur J Pharmacol       Date:  1994-03-11       Impact factor: 4.432

4.  Relative anticonvulsant effects of GABAmimetic and GABA modulatory agents.

Authors:  K D Holland; A C McKeon; D J Canney; D F Covey; J A Ferrendelli
Journal:  Epilepsia       Date:  1992 Nov-Dec       Impact factor: 5.864

5.  Ischemic neuronal injury in the rat hippocampus following transient forebrain ischemia: evaluation using in vivo microdialysis.

Authors:  K Matsumoto; S Ueda; T Hashimoto; K Kuriyama
Journal:  Brain Res       Date:  1991-03-15       Impact factor: 3.252

6.  Neuroprotective activity of chlormethiazole following transient forebrain ischaemia in the gerbil.

Authors:  A J Cross; J A Jones; H A Baldwin; A R Green
Journal:  Br J Pharmacol       Date:  1991-10       Impact factor: 8.739

Review 7.  Vigabatrin. Clinical pharmacokinetics.

Authors:  E Rey; G Pons; G Olive
Journal:  Clin Pharmacokinet       Date:  1992-10       Impact factor: 6.447

8.  Gamma-vinyl GABA prevents hippocampal and substantia nigra reticulata damage in repetitive transient forebrain ischemia.

Authors:  A Shuaib; S Ijaz; S Hasan; J Kalra
Journal:  Brain Res       Date:  1992-09-11       Impact factor: 3.252

9.  Human copper-zinc superoxide dismutase transgenic mice are highly resistant to reperfusion injury after focal cerebral ischemia.

Authors:  G Yang; P H Chan; J Chen; E Carlson; S F Chen; P Weinstein; C J Epstein; H Kamii
Journal:  Stroke       Date:  1994-01       Impact factor: 7.914

10.  Vigabatrin as an anticonvulsant against pentylenetetrazol seizures.

Authors:  U Sayin; S Cengiz; T Altug
Journal:  Pharmacol Res       Date:  1993-12       Impact factor: 7.658

View more
  4 in total

1.  Migraine prophylaxis, ischemic depolarizations, and stroke outcomes in mice.

Authors:  Katharina Eikermann-Haerter; Jeong Hyun Lee; Nilufer Yalcin; Esther S Yu; Ali Daneshmand; Ying Wei; Yi Zheng; Anil Can; Buse Sengul; Michel D Ferrari; Arn M J M van den Maagdenberg; Cenk Ayata
Journal:  Stroke       Date:  2014-11-25       Impact factor: 7.914

2.  Reducing GABAA-mediated inhibition improves forelimb motor function after focal cortical stroke in mice.

Authors:  Claudia Alia; Cristina Spalletti; Stefano Lai; Alessandro Panarese; Silvestro Micera; Matteo Caleo
Journal:  Sci Rep       Date:  2016-11-29       Impact factor: 4.379

Review 3.  Neuroplastic Changes Following Brain Ischemia and their Contribution to Stroke Recovery: Novel Approaches in Neurorehabilitation.

Authors:  Claudia Alia; Cristina Spalletti; Stefano Lai; Alessandro Panarese; Giuseppe Lamola; Federica Bertolucci; Fabio Vallone; Angelo Di Garbo; Carmelo Chisari; Silvestro Micera; Matteo Caleo
Journal:  Front Cell Neurosci       Date:  2017-03-16       Impact factor: 5.505

Review 4.  The Roles of GABA in Ischemia-Reperfusion Injury in the Central Nervous System and Peripheral Organs.

Authors:  Chaoran Chen; Xiang Zhou; Jialiang He; Zhenxing Xie; Shufang Xia; Guangli Lu
Journal:  Oxid Med Cell Longev       Date:  2019-11-11       Impact factor: 6.543

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.